Archive for the ‘BioTechnology – Venture Creation’ Category

Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes

Posted in Academic Publishing, Advanced Computing Platform, AI Models in Healthcare, Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Big Data, Big Data & Analytics, BioIT: BioInformatics, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Blockchain Transactions System, Centers for Medicare & Medicaid Services, Computational Biology/Systems and Bioinformatics, Curation, Data Science, Health Care System by Country, HealthCare IT, Innovations, Intelligent Information Systems, Machine Learning, Machine learning in predicting type 2 diabetes, Scientific Publishing, Technology Advance Assessment of, tagged AI in Healthcare, Artificial intelligence, Big data, databases, deep learning, Machine Learning, Machine Learning models, Medical history, Population-wide approach, type 2 diabetes on May 29, 2021| Leave a Comment »

Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes

Reporter: Amandeep Kaur, B.Sc., M.Sc.

A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. Researchers described their AI model as notable and distinctive based on the specific design which perform assessments at the population level.

**Machine Learning, big data and Artificial Intelligence in Healthcare System**
Image source: https://healthinformatics.uic.edu/blog/machine-learning-in-healthcare/

The first author Mathieu Ravaut, M.Sc. of the University of Toronto and other team members stated that “The main purpose of our model was to inform population health planning and management for the prevention of diabetes that incorporates health equity. It was not our goal for this model to be applied in the context of individual patient care.”

Research group collected data from 2006 to 2016 of approximately 2.1 million patients treated at the same healthcare system in Ontario, Canada. Even though the patients were belonged to the same area, the authors highlighted that Ontario encompasses a diverse and large population.

The newly developed algorithm was instructed with data of approximately 1.6 million patients, validated with data of about 243,000 patients and evaluated with more than 236,000 patient’s data. The data used to improve the algorithm included the medical history of each patient from previous two years- prescriptions, medications, lab tests and demographic information.

When predicting the onset of type 2 diabetes within five years, the algorithm model reached a test area under the ROC curve of 80.26.

The authors reported that “Our model showed consistent calibration across sex, immigration status, racial/ethnic and material deprivation, and a low to moderate number of events in the health care history of the patient. The cohort was representative of the whole population of Ontario, which is itself among the most diverse in the world. The model was well calibrated, and its discrimination, although with a slightly different end goal, was competitive with results reported in the literature for other machine learning–based studies that used more granular clinical data from electronic medical records without any modifications to the original test set distribution.”

This model could potentially improve the healthcare system of countries equipped with thorough administrative databases and aim towards specific cohorts that may encounter the faulty outcomes.

Research group stated that “Because our machine learning model included social determinants of health that are known to contribute to diabetes risk, our population-wide approach to risk assessment may represent a tool for addressing health disparities.”

Sources:

https://www.cardiovascularbusiness.com/topics/prevention-risk-reduction/new-ai-model-healthcare-data-predict-type-2-diabetes?utm_source=newsletter

Reference:

Ravaut M, Harish V, Sadeghi H, et al. Development and Validation of a Machine Learning Model Using Administrative Health Data to Predict Onset of Type 2 Diabetes. JAMA Netw Open. 2021;4(5):e2111315. doi:10.1001/jamanetworkopen.2021.11315 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780137

AI in Drug Discovery: Data Science and Core Biology @Merck &Co, Inc., @GNS Healthcare, @QuartzBio, @Benevolent AI and Nuritas

Reporters: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD

https://pharmaceuticalintelligence.com/2020/08/27/ai-in-drug-discovery-data-science-and-core-biology-merck-co-inc-gns-healthcare-quartzbio-benevolent-ai-and-nuritas/

Can Blockchain Technology and Artificial Intelligence Cure What Ails Biomedical Research and Healthcare

Curator: Stephen J. Williams, Ph.D.

https://pharmaceuticalintelligence.com/2018/12/10/can-blockchain-technology-and-artificial-intelligence-cure-what-ails-biomedical-research-and-healthcare/

HealthCare focused AI Startups from the 100 Companies Leading the Way in A.I. Globally

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/01/18/healthcare-focused-ai-startups-from-the-100-companies-leading-the-way-in-a-i-globally/

AI in Psychiatric Treatment – Using Machine Learning to Increase Treatment Efficacy in Mental Health

Reporter: Aviva Lev- Ari, PhD, RN

https://pharmaceuticalintelligence.com/2019/06/04/ai-in-psychiatric-treatment-using-machine-learning-to-increase-treatment-efficacy-in-mental-health/

Vyasa Analytics Demos Deep Learning Software for Life Sciences at Bio-IT World 2018 – Vyasa’s booth (#632)

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/05/10/vyasa-analytics-demos-deep-learning-software-for-life-sciences-at-bio-it-world-2018-vyasas-booth-632/

New Diabetes Treatment Using Smart Artificial Beta Cells

Reporter: Irina Robu, PhD

https://pharmaceuticalintelligence.com/2017/11/08/new-diabetes-treatment-using-smart-artificial-beta-cells/

Read Full Post »

The top 10 medtech M&A deals of 2020

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Medical Devices R&D Investment on April 14, 2021| Leave a Comment »

The top 10 medtech M&A deals of 2020

Reporter: Aviva Lev-Ari, PhD, RN

SOURCE

https://www.fiercebiotech.com/special-report/top-10-medtech-m-a-deals-2020?mkt_tok=Mjk0LU1RRi0wNTYAAAF8b8P08fCVQbG0SbLpWA3UUMD8cSMgviRFJa-h5SS2VqM_tzQe7KrH-azzlvoPTPPo5YR_TOFou992WYr7G5A-qtyq0U8pcxVCC57EWBRHl3RQYLU&mrkid=993697

Read Full Post »

Podcast Episodes by THE EUROPEAN VC

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital on February 12, 2021| Leave a Comment »

Podcast Episodes by THE EUROPEAN VC

Reporter: Aviva Lev-Ari, PhD, RN

Audio files are st:

The European VC

EPISODE #5: WILLIAM MCQUILLAN, FOUNDING PARTNER OF A VENTURE FIRM FOR GLOBALLY AMBITIOUS B2B COMPANIES

William is a founding partner of Frontline Ventures. Prior to starting Frontline, he was a founding employee at Ondra, an award-winning investment boutique that went from a 4 person team to 70+ employees in only 18 months. When Frontline was founded, William was 27 years old, making him the youngest VC ever to have raised a fund at that time (2012). Shortly after recording this episode William announced Frontline Fund III.

In this episode you will learn:

– How William has built a truly differentiated investment thesis for Frontline’s two funds.

– What William looks for in seed stage startups and why he believes integrity is all important and money cannot be the founder’s main driver.

– How William perceives the effects of Brexit and its implications for their investment strategy and work with startups.

– Why William is a supporter of founders taking a small bit of secondaries.

EPISODE #4: SHOMIT GHOSE, GP OF A SILICON VALLEY FIRM WITH 7 FUNDS UNDER ITS BELT

This episode runs contrary to what the European VC stands for and features an American VC from the Valley. However, the focus is on looking from the outside in, as well as carving out lessons learned from decades of collaboration across the Atlantic. Shomit Ghose is a General Partner of ONSET Ventures, a leading early stage venture firm operating out of Sand Hill Road, in Silicon Valley. With more than 130 startups and 7 funds under its belt, ONSET Ventures is a highly respected firm in the Valley. Shomit is a seasoned VC with multiple IPOs under his belt – both as an investor and as an entrepreneur.

In this episode you will learn:

– How the European and American VC landscapes differ and what we can learn from both.

– How to increase your presence and establish collaborations between US and European VCs.

– How to approach building a country-agnostic fund and the role of VCs, LPs and Institutions.

EPISODE #3 MICHAEL HANSEN, CEO OF A LEADING BUSINESS ANGEL ASSOCIATION IN EUROPE

Michael Hansen is the CEO of DanBAN, Denmark’s leading Business Angel Association. DanBAN consist of more than 200 active Angels who collectively invest in more than 30 M€ on an annual basis. Prior to joining DanBAN, Michael was the chief architect behind the sprawling investment environment around the Danish Robotics Cluster which is broadly recognized as one of the very strongest clusters for Robotics companies in Europe, if not the world.

In this episode, you will learn from a true investment cluster builder

– The importance of politicians making brave strategic decisions in promoting cluster development.

– The story of the Danish Robotics Cluster in which the first collaborative robots were hatched, counting with two acquisitions at a valuation of almost 1 billion EUR.

– How to work with national clusters to generate deal flow and fast track deals.

– Collaboration models between Business Angels and VCs.

EPISODE #2 STEPHAN MORAIS, FOUNDER AND MANAGING PARTNER OF A LEADING EARLY-STAGE DEEP TECH VC FIRM

Stephan Morais is the founder and Managing Partner of Indico Capital Partners, a leading early-stage deep tech VC firm. With a diversified background as an investment banker, consultant, entrepreneur and CEO, he has lived in 8 countries and 4 continents over the last 24 years, and acted as and advisor to politicians and European institutions. Prior to founding Indico, Stephan was an Executive Board Member at Caixa Capital, where he led investment rounds of many Portuguese global tech success stories.

In this episode, you’ll learn

– How Stephan tackled raising a VC fund and what to should look for in LPs

– How European VCs can push for policy developments that allow for more capital to be deployed into the industry

– What Europe can learn from other countries and regions

– What learnings Stephan has drawn from running an iberian fund

EPISODE #1 MARC LOHRMANN, MANAGING PARTNER OF A 120 M€ LIFE SCIENCE FUND

Marc Lohrmann is the Managing Partner of Vesalius Biocapital III, a 120 €M venture capital fund investing in late-stage companies in drug development, medical devices, diagnostics and eHealth, across Europe. Prior to joining Vesalius, Marc started eight life sciences companies, worked as an investment manager at a leading corporate VC and worked with several corporate finance boutiques focused on life sciences M&A transactions.

In this episode, you’ll learn

– How VBC III works as a country-agnostic VC fund and the main barriers to more funds investing across Europe.

– How investors without a natural sciences background can create value for Life Sciences companies and why founders find these investors a refreshing element in the board room.

– What Marc would love to change about European VC, what’s important when investing across Europe and what’s next for Marc.

SOURCE

https://www.theeuropeanvc.com/?utm_source=Sutardja%20Center%20Contacts&utm_campaign=f20d2f4f55-EMAIL_CAMPAIGN_2019_08_21_04_25_COPY_01&utm_medium=email&utm_term=0_8ae9d85a8f-f20d2f4f55-164676973

Read Full Post »

World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on January 18, 2021| Leave a Comment »

World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Reporter: Aviva Lev-Ari, PhD, RN

Davos Agenda

https://www.weforum.org/events/the-davos-agenda-2021

Adrian Monck, Managing Director, Public Engagement, public.affairs@weforum.org

日本語 | 中文 | عربي

World Leaders to Meet During Davos Agenda in a Crucial Year to Rebuild Trust

The Davos Agenda 2021 will convene under the theme: A Crucial Year to Rebuild Trust

The World Economic Forum will gather the world’s foremost leaders to address the economic, environmental, social and technological challenges following the COVID-19 pandemic

More than 1,500 business, government and civil society leaders from over 70 countries will set the agenda for a critical year ahead and discuss how to catalyse impact in the rapidly advancing Fourth Industrial Revolution

The conclusions from the Davos Agenda week will feed into task forces working on global issues for the upcoming Special Annual Meeting in Singapore

For more information, please visit http://www.weforum.org; share on social media using the hashtag #DavosAgenda

Geneva, Switzerland, 18 January 2021 – The World Economic Forum Davos Agenda, taking place virtually on 25-29 January, will bring together the foremost leaders of the world to address the new global situation. Heads of state and government, chief executives and leaders from civil society will convene under the theme: A Crucial Year to Rebuild Trust.

The meeting will focus on creating impact, rebuilding trust and shaping the policies and partnerships needed in 2021.

“In the context of the COVID-19 pandemic, the need to reset priorities and the urgency to reform systems have been growing stronger around the world,” said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. “Rebuilding trust and increasing global cooperation are crucial to fostering innovative and bold solutions to stem the pandemic and drive a robust recovery. This unique meeting will be an opportunity for leaders to outline their vision and address the most important issues of our time, such as the need to accelerate job creation and to protect the environment.”

The COVID-19 pandemic has demonstrated that no institution or individual alone can address the economic, environmental, social and technological challenges of our complex, interdependent world. The pandemic has accelerated systemic changes that were apparent before its inception. The fault lines that emerged in 2020 now appear as critical crossroads in 2021. The Davos Agenda will help leaders choose innovative and bold solutions to stem the pandemic and drive a robust recovery over the next year.

The five programme themes are:

Designing cohesive, sustainable, resilient economic systems (25 January)

Driving responsible industry transformation and growth (26 January)

Enhancing stewardship of the global commons (27 January)

Harnessing the technologies of the Fourth Industrial Revolution (28 January)

Advancing global and regional cooperation (29 January)

Special addresses from G20 heads of state and government and international organizations will provide crucial insights into a range of important issues in the year ahead. Participants will hear first-hand how these public figures will demonstrate leadership and drive action in areas such as the environment, jobs, and advances in innovation brought by the Fourth Industrial Revolution.

Heads of state and government include:

Xi Jinping, President of the People’s Republic of China; Narendra Modi, Prime Minister of India; Yoshihide Suga, Prime Minister of Japan; Emmanuel Macron, President of France; Angela Merkel, Federal Chancellor of Germany; Ursula von der Leyen, President of the European Commission; Giuseppe Conte, Prime Minister of Italy; Moon Jae-in, President of the Republic of Korea; Alberto Fernández, President of Argentina; Cyril Ramaphosa, President of South Africa; Pedro Sánchez, Prime Minister of Spain; Guy Parmelin, President of the Swiss Confederation and Federal Councillor for Economic Affairs, Education and Research; Ivan Duque, President of Colombia; Carlos Alvarado Quesada, President of Costa Rica; Nana Addo Dankwa Akufo-Addo, President of the Republic of Ghana; Kyriakos Mitsotakis, Prime Minister of Greece; Benjamin Netanyahu, Prime Minister of Israel; Abdullah II ibn Al Hussein, King of the Hashemite Kingdom of Jordan; Paul Kagame, President of Rwanda; Lee Hsien Loong, Prime Minister of Singapore, the host of the World Economic Forum Special Annual Meeting 2021.

Other world leaders are expected to confirm.

Leaders from international organizations, government agencies and central banks include:

António Guterres, Secretary-General, United Nations (UN); Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO); Kristalina Georgieva, Managing Director, International Monetary Fund (IMF); Amina Mohammed, Deputy Secretary-General, United Nations (UN); Achim Steiner, Administrator, United Nations Development Programme (UNDP); Phumzile Mlambo-Ngcuka, Undersecretary-General and Executive Director, United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN); Dongyu Qu, Director-General, Food and Agriculture Organization of the United Nations (FAO); Inger Andersen, Executive Director, United Nations Environment Programme (UNEP); Henrietta Fore, Executive Director, United Nations Children’s Fund (UNICEF); David Beasley, Executive Director, United Nations World Food Programme (WFP); Fang Liu, Secretary-General, International Civil Aviation Organization (ICAO); Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; Angel Gurría, Secretary-General, Organisation for Economic Co-operation and Development (OECD); Mauricio Claver-Carone, President, Inter-American Development Bank (IDB); Guy Ryder, Director-General, International Labour Organization (ILO); Jürgen Stock, Secretary-General, International Criminal Police Organization (INTERPOL); Fatih Birol, Executive Director, International Energy Agency (IEA); Rebecca Fatima Sta Maria, Executive Director, APEC Secretariat (Asia-Pacific Economic Cooperation).

Christine Lagarde, President, European Central Bank; François Villeroy de Galhau, Governor of the Central Bank of France; Andrew Bailey, Governor of the Bank of England.

The private sector will be represented by more than 1,000 leaders from the Forum’s member and partner organizations. Seven of the top ten companies by market capitalization are engaged year-round with the Forum and many will participate in The Davos Agenda week. As a working meeting to advance ongoing project work, more than 500 chief executives and chairpersons will take part in sessions throughout the week.

Leaders from civil society are a critical voice in shaping the agenda. Those taking part in the meeting include:

Seth Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance; Gabriela Bucher, Executive Director, Oxfam International; Sharan Burrow, General Secretary, International Trade Union Confederation (ITUC); Hindou Oumarou Ibrahim, President, Association for Indigenous Women and Peoples of Chad (AFPAT); Marco Lambertini, Director-General, WWF International; Laura Liswood, Secretary-General, Council of Women World Leaders; Delia Ferreira Rubio, Chair, Transparency International; Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria (GF).

Drawn from over 10,000 civic-minded young leaders, members of the World Economic Forum’s Global Shapers, Young Global Leaders, Technology Pioneers and Social Entrepreneurs communities will bring unique perspectives to The Davos Agenda.

Flagship reports, initiatives, and the latest book on Stakeholder Capitalism

On January 25, Professor Schwab will release his latest book, titled “Stakeholder Capitalism: A Global Economy that Works for Progress, People and Planet.” It explores how societies can build the future post-COVID, and builds on the Forum’s 50-year-old advocacy of the stakeholder approach.

The World Economic Forum will release its Global Risks Report 2021 on 19 January. The flagship report is an important marker for prioritizing action in public and private sectors in the year ahead.

The Davos Agenda will also mark the launch of several World Economic Forum initiatives to accelerate the race to net-zero emissions, to champion new standards for racial justice, to ensure artificial intelligence is developed ethically and in the global public interest and to close the digital divide. More details on these initiatives and others will be disclosed at the meeting.

Opening Event and Crystal Awards

The meeting will be preceded by the Opening Event, available on YouTube on Sunday 24 January at 19.00 CET, featuring a welcome from Klaus Schwab and a special address by Guy Parmelin, President of the Swiss Confederation, just before the 27th Crystal Awards hosted by Hilde Schwab, Chairperson and Co-founder, Schwab Foundation for Social Entrepreneurship, and the photographer Platon.

The awards will be followed by the world premiere of “See Me: A Global Concert.” The official programme of The Davos Agenda will begin on 25 January.

Notes to editors

Media registration and sign-up

Explore the guide on how to follow and embed sessions on your website here

Watch the livestreamed sessions here

Follow the Forum on Twitter via @wef @davos and join the conversation using #DavosAgenda | Instagram | LinkedIn | TikTok | Weibo | Podcasts

Become a fan of the Forum on Facebook

Read the Forum Agenda also in French | Spanish | Mandarin | Japanese

Check out the Forum’s Strategic Intelligence Platform and Transformation Maps

Watch Forum videos

Learn about the Forum’s impact

Subscribe to Forum news releases and Podcasts

SOURCE

From: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Reply-To: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Date: Monday, January 18, 2021 at 9:37 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Read Full Post »

Joe Biden Announced Science Team Nominations for the New Administration

Posted in and Bioethics, Biological Engineering, Evidence-based decision-making, Foundations for supporting Science and Education, Funding Opportunities for Cancer Research, Health Law & Patient Safety, Health Law Policy, HealthCare IT, Interviews with Key Opinion Leaders (KOLs), Leadership, Power, Social Interlocking Connections, National Academy of Sciences AWARDS, Nobel Prize WInners, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, Women in Life Sciences, women in science, tagged aerospace, bioengineering, Broad Institute, Eric Lander, genomics, global warming, Human Genome Project, Joe Biden, MIT, nobel leureates, precision medicine, Princeton University, Science Advisory Panel, science policy, US science on January 17, 2021| Leave a Comment »

Joe Biden Announced Science Team Nominations for the New Administration

Reporter: Stephen J. Williams, PhD

UPDATED on 1/18/2021

As we move forward, we should all take pride in the continuation of UC Berkeley’s legacy of service and leadership to our political, economic and civic institutions. We congratulate alumni and faculty of the social sciences playing prominent roles in the incoming administration. Dr. Lisa D. Cook (‘04 Ph.D., Economics) is leading the economic transition team. Professor Emeritus Janet Yellen , (Berkeley Haas, Berkeley Economics) is the first woman nominated to serve as Secretary of the Treasury; Wally Adeyemo (‘03 Political Economy) is the first African-American to serve as the Deputy Secretary of the Treasury; and Alejandro Mayorkas (‘81 History) is both the first Latino American and the first Jewish American nominated as Director of Homeland Security.

SOURCE

From: Dean Raka Ray <socialsciences@berkeley.edu>

Reply-To: “socialsciences@berkeley.edu” <reply-fe841079776d017a72-101_HTML-19495415-7300855-42@our.berkeley.edu>

Date: Monday, January 18, 2021 at 11:01 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: A message from the Dean of Social Sciences

JANUARY 16, 2021

Biden Science Team Nominations

President-elect Joe Biden and Vice President-elect Kamala Harris announced several members of their White House science team. Eric Lander is the nominee for director of the Office of Science and Technology Policy, elevated to a Cabinet-level position. Mr. Biden also selected Alondra Nelson for deputy director of the President’s Council of Advisers on Science and Technology, and appointed Frances Arnold and Maria Zuber as co-chairs of the Office of Science and Technology Policy.

MP4 video – Standard

Price:

$4.99

ADD TO BASKET
MP3 audio – Standard

Price:

$0.99

ADD TO BASKET

In an announcement televised on C-Span, President Elect Joseph Biden announced his new Science Team to advise on science policy matters, as part of the White House Advisory Committee on Science and Technology. Below is a video clip and the transcript, also available at

https://www.c-span.org/video/?508044-1/president-elect-biden-introduces-white-house-science-team

The video link is

https://www.c-span.org/video/?508044-1/president-elect-biden-introduces-white-house-science-team

COMING UP TONIGHT ON C-SPAN, NEXT, PRESIDENT-ELECT JOE BIDEN AND VICE PRESIDENT-ELECT KAMALA HARRIS ANNOUNCE SEVERAL MEMBERS OF THEIR WHITE HOUSE SCIENCE TEAM. AND THEN SENATE MINORITY LEADER CHUCK SCHUMER TALKS ABOUT THE IMPEACHMENT OF PRESIDENT TRUMP IN THE WEEKLY DEMOCRATIC ADDRESS. AND AFTER THAT, TODAY’S SPEECH BY VICE PRESIDENT MIKE PENCE TO SAILORS AT NAVAL AIR STATION LAMORE IN CALIFORNIA. NEXT, PRESIDENT-ELECT JOE BIDEN AND VICE PRESIDENT-ELECT KAMALA HARRIS ANNOUNCE SEVERAL MEMBERS OF THEIR WHITE HOUSE SCIENCE TEAM. FROM WILMINGTON, DELAWARE, THIS IS ABOUT 40 MINUTES. PRESIDENT-ELECT BIDEN: GOOD AFTERNOON, FOLKS. I WAS TELLING THESE FOUR BRILLIANT SCIENTISTS AS I STOOD IN THE BACK, IN A WAY, THEY — THIS IS THE MOST EXCITING ANNOUNCEMENT THAT I’VE GOTTEN TO MAKE IN THE ENTIRE CABINET RAISED TO A CABINET LEVEL POSITION IN ONE CASE. THESE ARE AMONG THE BRIGHTEST MOST DEDICATED PEOPLE NOT ONLY IN THE COUNTRY BUT THE WORLD. THEY’RE COMPOSED OF SOME OF THE MOST SCIENTIFIC BRILLIANT MINDS IN THE WORLD. WHEN I WAS VICE PRESIDENT AS — I I HAD INTENSE INTEREST IN EVERYTHING THEY WERE DOING AND I PAID ENORMOUS ATTENTION. AND I WOULD — LIKE A KID GOING BACK TO SCHOOL. SIT DOWN AND CAN YOU EXPLAIN TO ME AND THEY WERE — VERY PATIENT WITH ME. AND — BUT AS PRESIDENT, I WANTED YOU TO KNOW I’M GOING TO PAY A GREAT DEAL OF ATTENTION. WHEN I TRAVEL THE WORLD AS VICE PRESIDENT, I WAS OFTEN ASKED TO EXPLAIN TO WORLD LEADERS, THEY ASKED ME THINGS LIKE DEFINE AMERICA. TELL ME HOW CAN YOU DEFINE AMERICA? WHAT’S AMERICA? AND I WAS ON A TIBETAN PLATEAU WITH AT THE TIME WITH XI ZIN PING AND WE HAD AN INTERPRETER CAN I DEFINE AMERICA FOR HIM? I SAID YES, I CAN. IN ONE WORD. POSSIBILITIES. POSSIBILITIES. I THINK IT’S ONE OF THE REASONS WHY WE’VE OCCASIONALLY BEEN REFERRED TO AS UGLY AMERICANS. WE THINK ANYTHING’S POSSIBLE GIVEN THE CHANCE, WE CAN DO ANYTHING. AND THAT’S PART OF I THINK THE AMERICAN SPIRIT. AND WHAT THE PEOPLE ON THIS STAGE AND THE DEPARTMENTS THEY WILL LEAD REPRESENT ENORMOUS POSSIBILITIES. THEY’RE THE ONES ASKING THE MOST AMERICAN OF QUESTIONS, WHAT NEXT? WHAT NEXT? NEVER SATISFIED, WHAT’S NEXT? AND WHAT’S NEXT IS BIG AND BREATHTAKING. HOW CAN — HOW CAN WE MAKE THE IMPOSSIBLE POSSIBLE? AND THEY WERE JUST ASKING QUESTIONS FOR THE SAKE OF QUESTIONS, THEY’RE ASKING THESE QUESTIONS AS CALL TO ACTION. , TO INSPIRE, TO HELP US IMAGINE THE FUTURE AND FIGURE OUT HOW TO MAKE IT REAL AND IMPROVE THE LIVES OF THE AMERICAN PEOPLE AND PEOPLE AROUND THE WORLD. THIS IS A TEAM THAT ASKED US TO IMAGINE EVERY HOME IN AMERICA BEING POWERED BY RENEWABLE ENERGY WITHIN THE NEXT 10 YEARS. OR 3-D IMAGE PRINTERS RESTORING TISSUE AFTER TRAUMATIC INJURIES AND HOSPITALS PRINTING ORGANS FOR ORGAN TRANSPLANTS. IMAGINE, IMAGINE. AND THEY REALLY — AND, YOU KNOW, THEN RALLY, THE SCIENTIFIC COMMUNITY TO GO ABOUT DOING WHAT WE’RE IMAGINING. YOU NEED SCIENCE, DATA AND DISCOVERY WAS A GOVERNING PHILOSOPHY IN THE OBAMA-BIDEN ADMINISTRATION. AND EVERYTHING FROM THE ECONOMY TO THE ENVIRONMENT TO CRIMINAL JUSTICE REFORM AND TO NATIONAL SECURITY. AND ON HEALTH CARE. FOR EXAMPLE, A BELIEF IN SCIENCE LED OUR EFFORTS TO MAP THE HUMAN BRAIN AND TO DEVELOP MORE PRECISE INDIVIDUALIZED MEDICINES. IT LED TO OUR ONGOING MISSION TO END CANCER AS WE KNOW IT, SOMETHING THAT IS DEEPLY PERSONAL TO BOTH MY FAMILY AND KAMALA’S FAMILY AND COUNTLESS FAMILIES IN AMERICA. WHEN PRESIDENT OBAMA ASKED ME TO LEAD THE CANCER MOON SHOT, I KNEW WE HAD TO INJECT A SENSE OF URGENCY INTO THE FIGHT. WE BELIEVED WE COULD DOUBLE THE RATE OF PROGRESS AND DO IN FIVE YEARS WHAT OTHERWISE WOULD TAKE 10. MY WIFE, JILL, AND I TRAVELED AROUND THE COUNTRY AND THE WORLD MEETING WITH THOUSANDS OF CANCER PATIENTS AND THEIR FAMILIES, PHYSICIANS, RESEARCHERS, PHILANTHROPISTS, TECHNOLOGY LEADERS AND HEADS OF STATE. WE SOUGHT TO BETTER UNDERSTAND AND BREAK DOWN THE SILOS AND STOVE PIPES THAT PREVENT THE SHARING OF INFORMATION AND IMPEDE ADVANCES IN CANCER RESEARCH AND TREATMENT WHILE BUILDING A FOCUSED AND COORDINATED EFFORT HERE AT HOME AND ABROAD. WE MADE PROGRESS. BUT THERE’S SO MUCH MORE THAT WE CAN DO. WHEN I ANNOUNCED THAT I WOULD NOT RUN IN 2015 AT THE TIME, I SAID I ONLY HAD ONE REGRET IN THE ROSE GARDEN AND IF I HAD ANY REGRETS THAT I HAD WON, THAT I WOULDN’T GET TO BE THE PRESIDENT TO PRESIDE OVER CANCER AS WE KNOW IT. WELL, AS GOD WILLING, AND ON THE 20TH OF THIS MONTH IN A COUPLE OF DAYS AS PRESIDENT I’M GOING TO DO EVERYTHING I CAN TO GET THAT DONE. I’M GOING TO — GOING TO BE A PRIORITY FOR ME AND FOR KAMALA AND IT’S A SIGNATURE ISSUE FOR JILL AS FIRST LADY. WE KNOW THE SCIENCE IS DISCOVERY AND NOT FICTION. AND IT’S ALSO ABOUT HOPE. AND THAT’S AMERICA. IT’S IN THE D.N.A. OF THIS COUNTRY, HOPE. WE’RE ON THE CUSP OF SOME OF THE MOST REMARKABLE BREAKTHROUGHS THAT WILL FUNDAMENTALLY CHANGE THE WAY OF LIFE FOR ALL LIFE ON THIS PLANET. WE CAN MAKE MORE PROGRESS IN THE NEXT 10 YEARS, I PREDICT, THAN WE’VE MADE IN THE LAST 50 YEARS. AND EXPONENTIAL MOVEMENT. WE CAN ALSO FACE SOME OF THE MOST DIRE CRISES IN A GENERATION WHERE SCIENCE IS CRITICAL TO WHETHER OR NOT WE MEET THE MOMENT OF PERIL AND PROMISE THAT WE KNOW IS WITHIN OUR REACH. IN 1944, FRANKLIN ROOSEVELT ASKED HIS SCIENCE ADVISOR HOW COULD THE UNITED STATES FURTHER ADVANCE SCIENTIFIC RESEARCH IN THE CRITICAL YEARS FOLLOWING THE SECOND WORLD WAR? THE RESPONSE LED TO SOME OF THE MOST GROUND BREAKING DISCOVERIES IN THE LAST 75 YEARS. AND WE CAN DO THAT AGAIN. AND WE CAN DO MORE. SO TODAY, I’M PROUD TO ANNOUNCE A TEAM OF SOME OF THE COUNTRY’S MOST BRILLIANT AND ACCOMPLISHED SCIENTISTS TO LEAD THE WAY. AND I’M ASKING THEM TO FOCUS ON FIVE KEY AREAS. FIRST THE PANDEMIC AND WHAT WE CAN LEARN ABOUT WHAT IS POSSIBLE OR WHAT SHOULD BE POSSIBLE TO ADDRESS THE WIDEST RANGE OF PUBLIC HEALTH NEEDS. SECONDLY, THE ECONOMY, HOW CAN WE BUILD BACK BETTER TO ENSURE PROSPERITY IS FULLY SHARED ALL ACROSS AMERICA? AMONG ALL AMERICANS? AND THIRDLY, HOW SCIENCE HELPS US CONFRONT THIS CLIMATE CRISIS WE FACE IN AMERICA AND THE WORLD BUT IN AMERICA HOW IT HELPS US CONFRONT THE CLIMATE CRISIS WITH AMERICAN JOBS AND INGENUITY. AND FOURTH, HOW CAN WE ENSURE THE UNITED STATES LEADS THE WORLD IN TECHNOLOGIES AND THE INDUSTRIES THAT THE FUTURE THAT WILL BE CRITICAL FOR OUR ECONOMIC PROSPERITY AND NATIONAL SECURITY? ESPECIALLY WITH THE INTENSE INCREASED COMPETITION AROUND THE WORLD FROM CHINA ON? AND FIFTH, HOW CAN WE ASSURE THE LONG-TERM HEALTH AND TRUST IN SCIENCE AND TECHNOLOGY IN OUR NATION? YOU KNOW, THESE ARE EACH QUESTIONS THAT CALL FOR ACTION. AND I’M HONORED TO ANNOUNCE A TEAM THAT IS ANSWERING THE CALL TO SERVE. AS THE PRESIDENTIAL SCIENCE ADVISOR AND DIRECTOR OF THE OFFICE OF SCIENCE AND TECHNOLOGY POLICY, I NOMINATE ONE OF THE MOST BRILLIANT GUYS I KNOW, PERSONS I KNOW, DR. ERIC LANDER. AND THANK YOU, DOC, FOR COMING BACK. THE PIONEER — HE’S A PIONEER IN THE STIFFING COMMUNITY. PRINCIPAL LEADER IN THE HUMAN GENOME PROJECT. AND NOT HYPERBOLE TO SUGGEST THAT DR. LANDER’S WORK HAS CHANGED THE COURSE OF HUMAN HISTORY. HIS ROLE IN HELPING US MAP THE GENOME PULLED BACK THE CURTAIN ON HUMAN DISEASE, ALLOWING SCIENTISTS, EVER SINCE, AND FOR GENERATIONS TO COME TO EXPLORE THE MOLECULAR BASIS FOR SOME OF THE MOST DEVASTATING ILLNESSES AFFECTING OUR WORLD. AND THE APPLICATION OF HIS PIONEERING WORK AS — ARE POISED TO LEAD TO INCREDIBLE CURES AND BREAKTHROUGHS IN THE YEARS TO COME. DR. LANDER NOW SERVES AS THE PRESIDENT AND FOUNDING DIRECTOR OF THE BRODE INSTITUTE AT M.I.T. AND HARVARD, THE WORLD’S FOREMOST NONPROFIT GENETIC RESEARCH ORGANIZATION. AND I CAME TO APPRECIATE DR. LANDER’S EXTRAORDINARY MIND WHEN HE SERVED AS THE CO-CHAIR OF THE PRESIDENT’S COUNCIL ON ADVISORS AND SCIENCE AND TECHNOLOGY DURING THE OBAMA-BIDEN ADMINISTRATION. AND I’M GRATEFUL, I’M GRATEFUL THAT WE CAN WORK TOGETHER AGAIN. I’VE ALWAYS SAID THAT BIDEN-HARRIS ADMINISTRATION WILL ALSO LEAD AND WE’RE GOING TO LEAD WITH SCIENCE AND TRUTH. WE BELIEVE IN BOTH. [LAUGHTER] GOD WILLING OVERCOME THE PANDEMIC AND BUILD OUR COUNTRY BETTER THAN IT WAS BEFORE. AND THAT’S WHY FOR THE FIRST TIME IN HISTORY, I’M GOING TO BE ELEVATING THE PRESIDENTIAL SCIENCE ADVISOR TO A CABINET RANK BECAUSE WE THINK IT’S THAT IMPORTANT. AS DEPUTY DIRECTOR OF THE OFFICE OF SCIENCE AND TECHNOLOGY POLICY AND SCIENCE AND — SCIENCE AND SOCIETY, I APPOINT DR. NELSON. SHE’S A PROFESSOR AT THE INSTITUTE OF ADVANCED STUDIES AT PRINCETON UNIVERSITY. THE PRESIDENT OF THE SOCIAL SCIENCE RESEARCH COUNCIL. AND ONE OF AMERICA’S LEADING SCHOLARS IN THE — AN AWARD-WINNING AUTHOR AND RESEARCHER AND EXPLORING THE CONNECTIONS BETWEEN SCIENCE AND OUR SOCIETY. THE DAUGHTER OF A MILITARY FAMILY, HER DAD SERVED IN THE UNITED STATES NAVY AND HER MOM WAS AN ARMY CRIPPING TO RAFFER. DR. NELSON DEVELOPED A LOVE OF TECHNOLOGY AT A VERY YOUNG AGE PARTICULARLY WITH THE EARLY COMPUTER PRODUCTS. COMPUTING PRODUCTS AND CODE-BREAKING EQUIPMENT THAT EVERY KID HAS AROUND THEIR HOUSE. AND SHE GREW UP WITHIN HER HOME. WHEN I WROTE THAT DOWN, I THOUGHT TO MYSELF, I MEAN, HOW MANY KIDS — ANY WAY, THAT PASSION WAS A PASSION FORGED A LIFELONG CURIOSITY ABOUT THE INEQUITIES AND THE POWER DIAMONDICS THAT SIT BENEATH THE SURFACE OF SCIENTIFIC RESEARCH AND THE TECHNOLOGY WE BUILD. DR. NELSON IS FOCUSED ON THOSE INSIGHTS. AND THE SCIENCE, TECHNOLOGY AND SOCIETY, LIKE FEW BEFORE HER EVER HAVE IN AMERICAN HISTORY. BREAKING NEW GROUND ON OUR UNDERSTANDING OF THE ROLE SCIENCE PLAYS IN AMERICAN LIFE AND OPENING THE DOOR TO — TO A FUTURE WHICH SCIENCE BETTER SERVES ALL PEOPLE. AS CO-CHAIR OF THE PRESIDENT’S COUNCIL ON ADVISORS OF SCIENCE AND TECHNOLOGY, I APPOINT DR. FRANCIS ARNOLD, DIRECTOR OF THE ROSE BIOENGINEERING CENTER AT CALTECH AND ONE OF THE WORLD’S LEADING EXPERTS IN PROTEIN ENGINEERING, A LIFE-LONG CHAMPION OF RENEWABLE ENERGY SOLUTIONS WHO HAS BEEN INDUCTED INTO THE NATIONAL INVENTORS’ HALL OF FAME. THAT AIN’T A BAD PLACE TO BE. NOT ONLY IS SHE THE FIRST WOMAN TO BE ELECTED TO ALL THREE NATIONAL ACADEMIES OF SCIENCE, MEDICINE AND ENGINEERING AND ALSO THE FIRST WOMAN, AMERICAN WOMAN, TO WIN A NOBEL PRIZE IN CHEMISTRY. A VERY SLOW LEARNER, SLOW STARTER, THE DAUGHTER OF PITTSBURGH, SHE WORKED AS A CAB DRIVER, A JAZZ CLUB SERVER, BEFORE MAKING HER WAY TO BERKELEY AND A CAREER ON THE LEADING EDGE OF HUMAN DISCOVERY. AND I WANT TO MAKE THAT POINT AGAIN. I WANT — IF ANY OF YOUR CHILDREN ARE WATCHING, LET THEM KNOW YOU CAN DO ANYTHING. THIS COUNTRY CAN DO ANYTHING. ANYTHING AT ALL. AND SO SHE SURVIVED BREAST CANCER, OVERCAME A TRAGIC LOSS IN HER FAMILY WHILE RISING TO THE TOP OF HER FIELD, STILL OVERWHELMINGLY DOMINATED BY MEN. HER PASSION HAS BEEN A STEADFAST COMMITMENT TO RENEWABLE ENERGY FOR THE BETTERMENT OF OUR PLANET AND HUMANKIND. SHE IS AN INSPIRING FIGURE TO SCIENTISTS ACROSS THE FIELD AND ACROSS NATIONS. AND I WANT TO THANK DR. ARNOLD FOR AGREEING TO CO-CHAIR A FIRST ALL WOMAN TEAM TO LEAD THE PRESIDENT’S COUNCIL OF ADVISORS ON SCIENCE AND TECHNOLOGY WHICH LEADS ME TO THE NEXT MEMBER OF THE TEAM. AS CO-CHAIR, THE PRESIDENT’S COUNCIL OF ADVISORS ON SCIENCE AND TECHNOLOGY, I APPOINT DR. MARIE ZUBER. A TRAIL BLAZER BRAISING GEO PHYSICIST AND PLANETARY SCIENTIST A. FORMER CHAIR OF THE NATIONAL SCIENCE BOARD. FIRST WOMAN TO LEAD THE SCIENCE DEPARTMENT AT M.I.T. AND THE FIRST WOMAN TO LEAD NASA’S ROBOTIC PLANETARY MISSION. GROWING UP IN COLE COUNTRY NOT FAR FROM HEAVEN, SCRANTON, PENNSYLVANIA, IN CARBON COUNTY, PENNSYLVANIA, ABOUT 50 MILES SOUTH OF WHERE I WAS A KID, SHE DREAMED OF EXPLORING OUTER SPACE. COULD HAVE TOLD HER SHE WOULD JUST GO TO GREEN REACH IN SCRANTON AND FIND WHERE IT WAS. AND I SHOULDN’T BE SO FLIPPANT. BUT I’M SO EXCITED ABOUT THESE FOLKS. YOU KNOW, READING EVERY BOOK SHE COULD FIND AND LISTENING TO HER MOM’S STORIES ABOUT WATCHING THE EARLIEST ROCKET LAUNCH ON TELEVISION, MARIE BECAME THE FIRST PERSON IN HER FAMILY TO GO TO COLLEGE AND NEVER LET GO OF HER DREAM. TODAY SHE OVERSEES THE LINCOLN LABORATORY AT M.I.T. AND LEADS THE INSTITUTION’S CLIMATE ACTION PLAN. GROWING UP IN COLD COUNTRY, NOT AND FINALLY, COULD NOT BE HERE TODAY, BUT I’M PLEASED TO ANNOUNCE THAT I’VE HAD A LONG CONVERSATION WITH DR. FRANCIS COLLINS AND COULD NOT BE HERE TODAY. AND I’VE ASKED THEM TO STAY ON AS DIRECTOR OF THE INSTITUTE OF HEALTH AND — AT THIS CRITICAL MOMENT. I’VE KNOWN DR. COLLINS FOR MANY YEARS. I WORKED WITH HIM CLOSELY. HE’S BRILLIANT. A PIONEER. A TRUE LEADER. AND ABOVE ALL, HE’S A MODEL OF PUBLIC SERVICE AND I’M HONORED TO BE WORKING WITH HIM AGAIN. AND IT IS — IN HIS ABSENCE I WANT TO THANK HIM AGAIN FOR BEING WILLING TO STAY ON. I KNOW THAT WASN’T HIS ORIGINAL PLAN. BUT WE WORKED AN AWFUL LOT ON THE MOON SHOT AND DEALING WITH CANCER AND I JUST WANT TO THANK HIM AGAIN. AND TO EACH OF YOU AND YOUR FAMILIES, AND I SAY YOUR FAMILIES, THANK YOU FOR THE WILLINGNESS TO SERVE. AND NOT THAT YOU HAVEN’T BEEN SERVING ALREADY BUT TO SERVE IN THE ADMINISTRATION. AND THE AMERICAN PEOPLE, TO ALL THE AMERICAN PEOPLE, THIS IS A TEAM THAT’S GOING TO HELP RESTORE YOUR FAITH IN AMERICA’S PLACE IN THE FRONTIER OF SCIENCE AND DISCOVER AND HOPE. I’M NOW GOING TO TURN THIS OVER STARTING WITH DR. LANDER, TO EACH OF OUR NOMINEES AND THEN WITH — HEAR FROM THE VICE PRESIDENT. BUT AGAIN, JUST CAN’T THANK YOU ENOUGH AND I REALLY MEAN IT. THANK YOU, THANK YOU, THANK YOU FOR WILLING TO DO THIS. DOCTOR, IT’S ALL YOURS. I BETTER PUT MY MASK ON OR I’M GOING TO GET IN TROUBLE.

Director’s Page

Read Full Post »

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures: Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital on January 6, 2021| Leave a Comment »

Venture Summit Virtual Connect West, March 16^th -18^th 2021 featuring a dedicated Lifesciences / Healthcare Track

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

UPDATED on 2/17/2021

Venture Summit Virtual Connect West Early Bird rates were extended to this Thursday, February 18^th at midnight (EST). Would it be possible to share the dedicated discount code LPBIVIP again with your network? Included updated social media copy below.

The discount code will still operate when the rates increase but applicants should apply asap to lock in the lowest possible rates. Registration closes around March 11^th.

Partial roster of over 170 VCs and Angels Confirmed to Speak and Judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Coleman Adams, Partner, CEVG | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Salman Azhar, Founding Partner & Managing Director, Azhar Private Equity | Afonso Babo, Co-managing director, COREangels Impact | Sion Balass, Partner, The Group Ventures | Assaf Barnea, CEO, Sanara Ventures | Hasan Basrai, Associate, Information Venture Partners | Randy Berholtz, Investor Judge, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Reetika Bhardwaj, Associate, ARCH Venture Partners | Udit Bhatnagar, Vice President, McRock Capital | Jason Blumberg, CEO/Managing Partner, Energy Foundry | Christopher Booker, Partner, Frist Cressey Ventures | Alice Brooks, Principal, Khosla Ventures | Alex Brufsky, Venture Partner, 1435 Capital | Edouard Bulteau, Principal, Total Carbon Neutrality Ventures | Ryuk Byun, Associate, Aisling Capital | James Carroll, Managing Partner, CC Angel Investments | Adam Carson, Operating Partner, Point72 Ventures | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Andre Chabaneix, Associate, Blue Bear Capital | Iris Chan, Partner, Mighty Capital | Ray Chan, Managing Director, K5 Ventures | Jonathan Charles, Director, Samsung Catalyst Fund | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Ryan Chou, Investment Associate, JetBlue Technology Ventures | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Rick Cutright, Technology Principal, OGCI Climate Investments | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Investment Partner, Joyance Partners | Eric Desai, Partner, Greenhouse Capital Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Francesco Draetta, Principal, Omega Funds | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Manny Fernandez, Angel Investor, SF Angels Group | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Tarik Galijasevic, Managing Director, Allstate Strategic Ventures | Elena Gantvarg, Principal, Flint Capital | Chris Garabedian, CEO, Xontogeny | Daisy Garcia, Investment Analyst, JetBlue Technology Ventures | Joe Garcia, Venture Fellow, Rethink Impact | Selma Gasc, Investment Analyst, 360 Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | Michal Geva, Co-Founder and Managing Partner, Triventures | Shmuel Gniwisch, Managing Partner/Co-founder, Kli Capital | David Goldberg, General Partner, Alpaca VC | Garrett Goldberg, Partner, Bee Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Deepak Gupta, Managing Partner, Blue Bear Ventures | Katie Hayes, Director, Wittington Ventures | Yashwanth Hemaraj, Partner, Benhamou Global Ventures | Thomas Henry, Co-Founder COO, Eunike Ventures | Robert Hess, Angel Investor, Life Science Angels | David Hornik, Partner, August Capital | Kirsten Horning, Principal, XRC Labs | Galit Horovitz, Co-founder, Welltech1 | Conor Hunt, Principal, 1435 Capital | Noel Jee, Principal, Illumina Ventures | Ben Jen, Managing Director, Ben Jen Holdings | Denis Kalyshkin, Principal, I2BF Global Ventures | Tomas Kemtys, Partner, Contrarian Ventures | Hunter Kettering, VC, Red Cedar Ventures | Maureen Klewicki, Investor, Crosscut Ventures | Howard Ko, Principal, Morpheus Ventures | John-Paul Lake, Managing Partner, Kern Venture Group | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Ephraim Lindenbaum, Managing Director, Advance Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Brian Litvak, Market Development, Aster Capital | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Ventures | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Radhika Malik, Investment Manager, Samsung Catalyst Fund | Alex Mayall, Associate, Anthemis Group | Melissa McCracken, Principal, Nextech Invest | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Inka Mero, Founder & Managing Partner, Voima Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Olivia Musmanno, Senior Associate, Quake Capital | Molly O’Shea, Investor, NYL Ventures | Gilbert Ohana, Managing Partner, FinTLV Ventures | Victor Orlovski, Managing Partner, Fort Ross Ventures | Shamik Parekh, Investment Associate, Octopus Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Michael Peri, Senior Vice President, NFP Ventures | Michael Perry, Associate, Link Ventures | Daniel Pianko, Managing Director, Achieve Partners | Patricia Poon, Director, Belmond Capital | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | Julia Reichelstein, Investor, Piva Capital | John Robinson, Partner, Mazarine Ventures | Carolina Rojas, Ventures Analyst, NFP Ventures | Stephen Roland, Associate, Swiftarc Ventures | Alexander Ross, Investment Director, Illuminate Financial | Joseph Rothman, Venture Partner, AlphaPrime Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Abinav Sankar, Partner, Sopris Capital | Stephanie Sarelakos, VP, Investments, The Venture Collective | Massimo Schäppi, Partner, Tomahawk .VC | Reese Schroeder, Investor, Allstate Strategic Ventures | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Shounok Sinha, Principal, Venture Investing, Constellation Technology Ventures | Michelle Snyder, Partner, McKesson Ventures | Vivek Soni, Venture Partner, S CAP CleanTech | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Alexander Starchenko, Managing Partner, First Imagine! Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Ning Sung, Investor, Sandhill Angels | Daniel Teo, Managing Partner, Hunniwell Lake Ventures | Byron Thom, Principal, Framework Venture Partners | Abhinav Tiwari, General Partner, Owl Capital | Erica Van, Investor, Charles River Ventures | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Alexander Vavilov, Investment Manager, iTech Capital | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Isaiah Washington, Analyst, Insight Partners | Lauren Weston, Associate, Thomvest Ventures | Sarah Wolter, Principal, FinTech Collective | Minjia Wu, Principal, SOSV | Yating Xia, Investor, TCL | Steve Yaskin, Venture Partner, Scale Up Ventures | Juan Zavala, Principal, New Markets Venture Partners | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chen Zhou, Investor, Samsung Catalyst Fund and many more…

Regards,

Gil

Gil Garalnick

Senior Associate

youngStartup Ventures

“Where Innovation Meets Capital”

p: 212.202.1002 ext 208

e: gil@youngstartup.com

u: www.youngstartup.com

UPDATED on 1/21/2021

Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

* Call for Top Innovators Details below

Venture Summit Virtual Connect West

Where Innovation Meets Capital

March 16^th -18^th 2021

Friends,

Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16^th-18^th 2021, featuring a dedicated Lifesciences / Healthcare track.

Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, ‎Industry executives and founders of venture backed, emerging and early stage companies; will feature ‎One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and ‎Keynotes.

Partial roster of over VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Sion Balass, Partner, The Group Ventures | Randy Berholtz, Senior Advisor, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Udit Bhatnagar, Vice President, McRock Capital | Christopher Booker, Partner, Frist Cressey Ventures | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Jun Deng, Investment Partner, Joyance Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Elena Gantvarg, Principal, Flint Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | David Goldberg, General Partner, Alpaca VC | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Katie Hayes, Director, Wittington Ventures | Robert Hess, Angel Investor, Life Science Angels | Kirsten Horning, Principal, XRC Labs | Ben Jen, Managing Director, Ben Jen Holdings | Hunter Kettering, VC, Red Cedar Ventures | Howard Ko, Principal, Morpheus Ventures | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Americas | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Molly O’Shea, Investor, NYL Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Daniel Pianko, Managing Director, Achieve Partners | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | John Robinson, Partner, Mazarine Ventures | Stephen Roland, Associate, Swiftarc Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Massimo Schäppi, Partner, Tomahawk .VC | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Byron Thom, Principal, Framework Venture Partners | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Lauren Weston, Associate, Thomvest Ventures | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

Register Today & Save Click here http://bit.ly/3840e3D . (Use promo code “LPBIVIP”)

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

We look forward to seeing you there.

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

* Call for Top Innovators Details below

Venture Summit Virtual Connect West

Where Innovation Meets Capital

March 16^th -18^th 2021

Register Today & Save

Click here http://bit.ly/3840e3D

(Use promo code “LPBIVIP”)

Friends,

Partial roster of VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Timur Davis, Principal, Munich Re Ventures | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Andrew Felbinger, Investor, Urban Innovation Fund | Gary Gershony, Founding General Partner, BayMed Venture Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Kirsten Horning, Principal, XRC Labs | Hunter Kettering, VC, Red Cedar Ventures | Rachel Lauren, Analyst, BDMI | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Matt Murphy, Partner, Montage Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nia Stefani, CEO, Xnergy Financial | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

Special Offer:

Register Today & Save Click here http://bit.ly/3840e3D

(Use promo code “LPBIVIP”)

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

We look forward to seeing you there.

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

LinkedIn

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16^th– 18^th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Whether you are a Lifesciences / Healthcare investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.

Twitter

Join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16^th– 18^th 2021. Dedicated Lifesciences/Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Where do #startups connect with over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit Virtual Connect West being held on March 16^th – 18^th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register at http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Facebook

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect West being held on March 16^th – 18^th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Read Full Post »

Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as CEO and Arie Belldegrun, PhD on R&D

Posted in Bio Instrumentation in Experimental Life Sciences Research, Biological Engineering, Biological Networks, Gene Regulation and Evolution, Biomedical Measurement Science, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Gene Regulation, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Genomics Pharmacy on October 15, 2020| Leave a Comment »

Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as Chief Executive Officer and Arie Belldegrun, PhD (ex-Kite Therapeutics) on R&D

Curator & Reporter: Aviva Lev-Ari, PhD, RN

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

A new approach to biology

“The real voyage of discovery consists, not in seeking new landscapes, but in having new eyes.” Marcel Proust

Starting with the study of P granules in C.elegans embryos in 2009, Tony Hyman, working with his collaborators like Frank Julicher, Cliff Brangwynne, Simon Alberti, Mike Rosen, and Rohit Pappu, began to unravel the mysteries of biomolecular condensates. These scientists realized that P granules behave like liquid droplets that form by phase separation (think of oil droplets in salad dressing) and called them condensates.

In subsequent studies, they found to their surprise that many compartments inside cells had the behavior of condensates: they are liquid-like and form by phase separation.

Inspired by the work of Tony and his colleagues, Richard Young, Phillip Sharp, and Arup Chakraborty at MIT applied these approaches to the study of gene expression, similarly shedding light on many important questions in gene control.

Rick Young on condensates and gene control.

Tony Hyman on how cells form compartments. (From LatestThinking.org via CC BY 4.0; trimmed for length.)

Foundational Papers in Biomolecular Condensates

Germline P granules are liquid droplets that localize by controlled dissolution/condensation (Science, June 2009)

Liquid-Liquid Phase Separation in Biology (Annual Review of Cell & Developmental Biology, Oct 2014)

A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation (Cell, Aug 2015)

Biomolecular condensates: organizers of cellular biochemistry (Nature Review Cell Biology, Feb 2017)

A Phase Separation Model for Transcriptional Control. (Cell, March 2017)

Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains (Cell, Nov 2018)

SOURCE

https://dewpointx.com/

Press releases and Dewpoint in the news

Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer

October 13, 2020

Dewpoint

New York Times interviews Rick Young and Amy Gladfelter on the role of condensate “droplets” in COVID-19

October 9, 2020

New York Times

Dewpoint Therapeutics raises $77 million to go after ‘undruggable’ diseases

September 29, 2020

Boston Globe

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

September 29, 2020

Endpoint News

Dewpoint Therapeutics to put ‘pedal to the metal’ with $77M round

September 29, 2020

FierceBiotech

Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates

September 29, 2020

Dewpoint

21 biotech startups that are set to take off, according to top VCs

August 13, 2020

Business Insider

Proteins — and labs — coming together to prevent Rett Syndrome

July 22, 2020

Whitehead Institute

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

July 13, 2020

Dewpoint

Discovery of how cancer drugs find their targets could lead to a new toolset for drug development

June 18, 2020

Whitehead Institute

SOURCE

https://dewpointx.com/news/

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Posted in Big Data, BioSimilars, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, drug repurposing, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment on September 4, 2020| 1 Comment »

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

e-Proceedings 14^th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

Founder & Director, LPBI Group

https://pharmaceuticalintelligence.com/2020/07/28/14th-annual-biopharma-healthcare-summit-friday-september-4-2020-8-am-est-to-3-30-pm-est-virtual-edition/

Aviva Lev-Ari

@AVIVA1950

Speakers
Kenneth Frazier Chairman of the Board & CEO Merck & Co.	Dr. Andrew Plump President of R&D Takeda Pharmaceuticals	Dr. Laurie Glimcher President & CEO Dana-Farber Cancer Institute	Dr. Roy Vagelos Chairman of the Board Regeneron	Dr. Stelios Papadopoulos Chairman of the Board Biogen

Dr. Mathai Mammen Global Head of Janssen R&D Johnson & Johnson	Christopher Viehbacher Managing Partner Gurnet Point Capital	Hari Bhartia Founder & Co-Chairman Jubilant Bhartia Group	Dr. Hal Barron President, R&D and CSO GlaxoSmithKline	Prof. K. Vijay Raghavan Principal Scientific Advisor Government of India

Sanat Chattopadhyay President- Merck Manufacturing Division Merck & Co.	Dr. George Yancopoulos Co-Founder, President & CSO Regeneron	Kiran Mazumdar Shaw Executive Chairperson Biocon	Dr. Elias Zerhouni Professor Emeritus Johns Hopkins University	Dr. David Reese Executive Vice President- R&D Amgen

Dr. Alfred Sandrock Executive Vice President, R&D Biogen	Dr. Naresh Trehan Chairman Medanta – the Medicity	Dr. Najat Khan Chief Operating Officer, Data Sciences Janssen- Johnson & Johnson	Dr. Richard Hatchett Chief Executive Officer CEPI	Amitabh Kant Chief Executive Officer NITI Aayog

Dr. Martin Mackay Co-Founder Rallybio	Dr. Daniel Curran Head of the Rare Diseases TA Takeda Pharmaceuticals	Daphne Zohar Founder & CEO PureTech Health	Dr. David Meeker Chairman & CEO Rhythm Pharmaceuticals	Dr. John Orloff EVP and Head of R&D Alexion

Dr. Mandeep Bhandari Joint Secretary Ministry of Health, India	Dr. Barry Bloom Professor & former Dean Harvard School of Public Health	Dr. Anne Heatherington Head of Data Sciences Institute Takeda Pharmaceuticals	Dr. Philip Larsen Global Head of Research Bayer AG	Dr. Timothy Yu Assistant Professor in Pediatrics Harvard Medical School

Rehan Verjee President EMD Serono	Sastry Chilukuri Executive Vice President Medidata	Arpa Garay President, Commercial Analytics Merck & Co.	Dr. William Chin Professor of Medicine, Emeritus Harvard Medical School	Dr. V G Somani Drugs Controller General of India Government of India

Dr. Rajeev Venkayya President-Global Vaccines Takeda	Dr. Steve Uden Co-Founder Rallybio	Muna Bhanji SVP, Global Market Access Merck & Co.	Dr. Maya Said Chief Executive Officer Outcomes4Me	Dr. Raju Kucherlapati Professor of Genetics Harvard Medical School

Dr. Tony Ho Head of R&D CRISPR Therapeutics	Dr. Sanjeev Sinha Professor of Medicine All India Institute of Medical Sciences	Nina Kjellson General Partner Canaan	Dr. Michael Rosenblatt Chief Medical Officer Flagship Pioneering	Dr. Shiv Kumar Sarin Director Institute of Liver & Biliary Sciences

Matt Wilsey Co-Founder & Chairman Grace Science Foundation	Dr. Samuel Waksal Founder Meira GTx	Dr. Alise Reicin Former President, Global Clinical Dev. Celgene	Dr. Toni Choueiri Director Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute	Dr. Dhaval Patel EVP & Chief Scientific Officer UCB

Dr. Nirmal Kumar Ganguly Former Director General Indian Council of Medical Research	Dr. Peter Mueller President The Muller Health Foundation	Dr. Timothy Clackson President & CTO Xilio Therapeutics

Time	Topic
8 AM – 8-10 AM	Welcome address: Karun Rishi, President, USAIC COVID-19 Pandemic is a Global crisis India can play a special role in R&D and in Manufacturing including Vaccine development Opening comments: Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals Global Summit around the World – JP Morgan of the East as we were called – it is Now a Global Conference vs East Coast Record number of Drugs approved as New Drugs with special quality explosion of modality of therapies to include Gene Therapy Billion underserved vs N-of-One drug India’s President Modi allow healthcare access to 1/2Billion collaboration across the World COVID Alliance in vaccine development Global effort, China recovery is remarkable India battle the infection and it is growing – Public Health Remarkable Speakers
8-10 AM – 8-50 AM	Panel Discussion- COVID-19: Where are we now? Where are we going? Panelists: Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Testing – PCR expensive does not enable quick testing is expensive result come transmission occurred Antibody testing CRISPR test based Vaccine in clinical trials, public need to return for 2nd shot, hesitancy Who will get the Vaccine first? in the US most vulnerable of those causing transmission Pharma takes risk when efficacious level is unknown Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron Repurpose – be careful Ebola vaccine development approach is been REUSED for COVID-19 Existential threat by Disease – preparedness is ridiculous as size of investment – far where we need to be Untreatable disease burden COVID-19 cost of healthcare calls massive increases as a society and Private sector Moderna invested in new technology from Academe to the Industry Universal HealthCare will cripple the the healthcare systems Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Safety in proof of concept Children focus for emergency use validation of repurpose drugs oral vaccine involve sequential processing, approval and TRUST, concerns about risks accelerate the process is the opportunity Dr. Rajeev Venkayya, President of the Global Vaccine Business Unit, Takeda Public confidence in COVID-19 Vaccine The Group with concerns at present is larger than 15 years ago due to the accelerate process od the development process political influences on CDC emergency authorization given prior to election hesitancy – influence of social media, conspiracies Transparency by Pharma and by Regulatory Agencies Independent reviews Dr. Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI) 78 countries ready to participate, Healthcare workers priority to be ready end of next year Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School
8-50 AM – 8-55 AM	Break + Polling
8-55 AM – 9-10 AM	India Regulatory update Dr. Mandeep Bhandari, Joint Secretary, Ministry of Health & Family Welfare, India COVID related – support for Clinical Trials support to the Industry, innovators, processes and infrastructure is in place Dr. V G Somani, Drug Controller General of India, Central Drug Control Organization partnership, time line, transparency interaction online with regulators 30 days approval pre and post approval – progress achieved Online presubmission very useful to both sides Ecosystems on early development: Gene therapy Moderator: Muna Bhanji, Senior Vice President, Merck & Co. India’s preparedness
9-10 AM – 9-15 AM	Break + Polling
9-15 AM – 9-55 AM	Fireside Chat Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit” AntiViral – nucleocide – orally bioavailable Vaccine in early development – BSV Vaccine used in EBOLA – attenuated virus vector platform experience – 1 single doze, deployed Globally Vaccine modified Measles Vaccine, novel platform – out patient and Hospital Antibiotic research at Merck – no market incentives on pricing for Merck to invest in antibiotics people will die from bacterial resistance infection and next pandemic will be bacterial not viral Moderator: Dr. Stelios Papadopoulos, Chairman of the Board, Biogen Most important comments on urgency in investment in drug development by multiple constituencies made by Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron Access to therapy
9-55 AM – 10 AM	Break + Polling
10 AM – 10-40 AM	India Innovation Landscape Panelists: Amitabh Kant, Chief Executive Officer, National Institution for Transforming India (NITI) Innovation in drug discovery collaboration for clinical trial infrastructure BioEconomy BioSimilar the largest number approved anywhere Incentives for size and scale Ingredients manufacturing to become India’s priority Investment in R&D and Human Capital in the BioEconomy Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group US history of innovations cluster and infrastructure: Academe, VC, small medium Biopharma, Government involvement India: Contract research – 20 years history, lagging the ability to take risk Changing, pricing of drug increased, innovating drug for local consumption, and it can be taken to US for a better price Cancer immunology in India under development India was Leading Chemistry Research – China’s government invested and took the market Indian companies bigger in size – free on requirement imposed on China India will be a great supplier to US Market to build high capacity raw materials Dr. K. Vijay Raghavan, Principal Scientific Advisor, Government of India Resources are necessary 30% from Industry vs Government and Academe with great students and labs Indian context – Personalized Medicine – Telemedicine and IT infrastructure allowing innovation in a 1Billion Population- sheer volume of quality professional Dr. Naresh Trehan, Chairman, Medanta – the Medicity Ecosystem ready for Government to promote innovations to conduct clinical trial with global acceptance standard diverse gene pool in population to innovate for new molecule to market Vaccine under development on Phase 1,2,3 – regulatory mechanism is in place genetic drugs, BioSimilar dominance in the market – biotech can do clinical trials in India vs abroad Moderator: Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co. Largest producer of generic drugs antiretroviral drug produced by Indian Pharma Biotech innovations growing middle class – how innovation , infrastructure and shift to research Diversify and become self reliance
10-40 AM – 10-45 AM	Break + Polling
10-45 AM – 11-25 AM	Panel Discussion- Oncology: Changing landscape- COVID learnings and the promise of new technologies Panelists: Dr. Alise Reicin, Former President, Global Clinical Development, Celgene Clinical trial were impacted by association of patients to trials anti bacterial resistance requires investment – needs will be greater for antibiotics in the future Cancer mutation next therapy biomarkers for mutations to be developed Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute Dana Farber saw impact of COVID-19 on immunosuppressant population of patients coming in for Cancer Tx – switch from IV Tx to Oral 96% decrease in screenings due to Pandemic – increase with Cancer diagnosis in coming years No clinical Trials in Cancer were suspended – all continued Telemedicine and working at home very efficient Genomics of COVID-19 studies at Dana Farber same pathway identifies safety and efficacy must be achieved – not to approve drugs without phase I & Phase II endpoints Dr. Philip Larsen, Global Head of Research, Bayer AG Repurposing drugs as antiviral from drug screening innovating methods Cytokine storm in OCVID-19 – kinase inhibitors may be antiviral – dat of tested positive allows research of pathway in new ways Regulatory agencies in US and Europe for types of drugs vs single patient drugs Rehan Verjee, President, EMD Serono entire volume of clinical trials at Roche went down same at EMD delay of 6 month, some were to be initiated but was put on hold Charities funding cancer research – were impacted and resources will come later and in decreased amount New opportunities support access to Medicine improve investment across the board Antibody cytotoxic with precision Dr. Tony Ho, Head of Research and Development, CRISPR Therapeutics challenges overcome by testing at home Moderator: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School New normal as a result of the pandemic role of personalized medicine Cancer cure – what are the prospects
11-25 AM – 11-30 AM	Break + Polling
11-30 AM – 12-10 PM	Panel Discussion- Industry & Investment Outlook Panelists: Christopher Viehbacher, Managing Partner, Gurnet Point Capital IPOs can have advantages in Pandemics – Travel curtails all deals done virtually in greater efficiency Drug pricing is a target by White house Dream of every Biotech – get Big Pharma coming to acquire and pay a lot Morph and adapt Daphne Zohar, Founder & CEO, PureTech Health kill project early financial incentive not in line in the industry incentive to move resources among project and kill early project experiments to find which project to kill Innovations – pattern recognition, fast followers academic translation Disease focus, best science is the decision factors Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University Digital Health CVS opens clinics R&D – Capital is low Network of global innovation hubs vc investor channel like in the past Value of company driven by hits blockbusters Dr. Stelios Papadopoulos, Chairman, Biogen Worst pandemic in our lifetime stock market if hot – in balance in supply and demand, interest rates low, excess supply of equities in entertainment, Travel, hospitality Healthcare was defensive therapeutics needed – opportunity to innovate in HC – shift money from entertainment, Travel hospitality to HC Recovery will shift money away from Healthcare IP Protection and patent expiration – biotech are cases not trends Moderator: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals Days of Genzyme please tell us about Christopher Viehbacher, Managing Partner, Gurnet Point Capital Moderator Presenter: Dr. Michael Rosenblatt, CEO
12-10 PM – 12-20 PM	Break + Polling
12-20 PM – 1 PM	Panel Discussion- Rare Diseases: No longer forgotten; but more to be achieved ROI is not there, regulatory requirements reduced, Registry Panelists: Dr. Alfred Sandrock, Executive Vice President, Research & Development, Biogen Multiple Sclerosis therapy cost effectiveness is not there vs save a life Appeal opportunity is there and regulators are people Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda Takeda collaborates with Grace Science Foundation Dr. David Meeker, Chairman & CEO , Rhythm Pharmaceuticals Cystic Fibrosis Dr. John Orloff, Head of Research & Development, Alexion ALS Duchenne Muscular Destrophy HUS ASO gene therapy – one time therapy: Valuation for the industry of long term therapy: US (long term non existence) vs Europe and Japan (much appreciated Matt Wilsey, Co-Founder & Chairman, Grace Science Foundation Ultra-rare (500 Patients) vs Ultra Ultra-rare (50 Patients) 70 patients in the World, Grace disease, Parent drive the search for drug Manufacturing cost comes down Price is dynamic Moderator: Dr. Steve Uden, Co-Founder, Rallybio Regulators are people
1 PM – 1-05 PM	Break + Polling
1-05 PM – 1-50 PM	Fireside Chat Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals Congratulate Big Pharma for taking the challenge on COVID-19 Vaccine, Antibody and anti-viral Government funding Merck was independent from Government – to be independent and be able to set the price HIV-AIDS: reverse transcriptase converted a lethal disease to a chronic disease, tried hard to make vaccine – the science was not there Industry role: Competition of drug discovery capacity is been built, global needs, price need be low for global reach Government is a already a player hoping without a control on pricing 300Million people were treated FREE by Merck’s Family Program HepC 9% in China immunize the newborn with HepB 1994 100% babies immunized – no profit to Merck – eradication of HepB in China Neuro degeneration – science supports drug development Role of R&D Scientists in Drug discovery? Moderator: Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson COVID-19 drug development: Response by Big Pharma Industry role in Access to medicines, biologics, antibodies, vaccines Role of R&D Scientists in Drug discovery? PAHTN – use Machine Learning on top of data collected routinely,
1-50 PM – 1-55 PM	Break + Polling
1-55 PM – 2-35 PM	Panel Discussion- Digital & Data Science in Healthcare: Pragmatic Insights from the Real-World Panelists: Dr. Anne Heatherington, Head of Data Sciences Institute, Takeda Pharmaceuticals Reliance on Data – AI and Data in Pharma alliance with MIT collaboration of Data for COVID-19 Women need education in STEM and in Data Science Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co. Data on Patients and identification who will benefit fro which therapy cultural bias risk aversion Invest early on in STEM Dr. Maya Said, Chief Executive Officer, Outcomes4Me Cancer patients taking change of their care Digital Health – consumerization of Health, patient demand to be part of the decision, part of the information FDA launched a Program Project Patient Voice Project Patient Voice is an online platform for patients and caregivers along with their healthcare providers to look at patient-reported symptom data collected from cancer clinical trials. https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice Women should not undersell themselves Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson Validation Deployment of algorithms embed data by type early on in the crisis to understand the disease Compare the Big IT-Data and Pharma where are the barriers? STEM and Women in Pharma – the opportunity must be right Nina Kjellson, General Partner, Canaan Data science is a winner in Healthcare Women – Data Science is an excellent match Moderator: Sastry Chilukuri, President, Acorn AI- Medidata Opportunities in Data Science in Pharma COVID-19 and Data Science STEM and Women in Pharma
2-35 PM – 2-40 PM	Break + Polling
2-40 PM – 3-20 PM	Panel Discussion- R&D Strategies and Trends: Innovation – The Big I Panelists: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals Enter for Plasma and for manufacturing vs discovery Change how pharma behaved inefficiently in the past – with COVID-19 new behaviors in the industry End of Century most diseases could be cured Dr. David Reese, Executive Vice President, Research and Development, Amgen Interaction with regulator was most favorable Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline Cytokine storm – few approaches Control molecule GSK owned GWAS not easy to find which gene drives the association Functional Genomics gene by gene with phenotypes using machine learning significant help Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson Neuro-modulation: Symptomology Outcomes – no correlation Vaccine platform used in the past for several vaccines: Selection process from several candidates, cell line enter Clinical waiting for data Using same platform with several proteins – great communality in the development Regulator deepen trust relationship which will carry for the future Pulmonologists and cardiologist in the COVIS-19 Patients – remove drugs monitoring on drugs Moderator: Duval Patel presented the Moderator Moderator: Martin Mackay, Co-Founder, RallyBio
3-20 PM – 3-30 PM	Closing Remarks Every year it is getting better India – innovate and make drugs for every country and for India Diversity and inclusion Leadership in Pharma Industry in all Panels Massive impact can be made

Polling Time (EST)	Polling Topic
8-50 AM	COVID-19 PanelQuestion 1: What do you foresee as the most likely outcome of the race to develop a vaccine? Heightened international tensions due to inequities in distribution Use of the vaccine as an instrument of geopolitics Collaboration between governments to use vaccine to end the pandemic All of the above Question 2: What minimum criteria would you like to see for approval of COVID19 vaccines, assuming adequate efficacy? Immune response in people over 60 years Durability of response Antibody plus T-cell response Emergency Use Authorization with caveats followed by final approval
9-10 AM	India Regulatory UpdateHow will MNCs respond to the recent regulatory changes for BioPharmas in India? They are _____ to run clinical trials there: More likely Less likely Equally likely
9-55 AM	Fireside Chat: Ken Frazier The BioPharma industry this year has publicly committed itself to greater diversity. What specific measures do you expect to see? Increasing diversity in clinical trials Increasing diversity at the C-suite and board level Increasing diversity throughout the company All of the above None of the above
10-40 AM	India Innovation LandscapeWhat is the most important step India could take to become a global leader in life sciences innovation?” Implement government policies to incentivize innovative drug development Increase availability of financing for BioPharmas Improve clinical trial infrastructure Increase IP protection
11-25 AM	Oncology PanelQuestion 1: Changes in policy and reimbursement over the next five years will impact innovation in cancer therapeutics Not at all Slightly Moderately Significantly Question 2: What therapeutic innovation do you think will have the biggest impact on cancer in the next five years? Cell-based immunotherapies Antibody-based immunotherapies Bispecific / multi-specific antibodies Antibody drug conjugates
12-10 PM	Industry & Investment Outlook PanelMore and more funding has been going into preclinical companies — do you expect this trend to continue? Yes No R&D Strategies and Trends Panel COVID-19 has led to an unprecedented level of collaboration among stakeholders in the biopharma industry. Where do you expect to see the biggest increase in collaborations post-pandemic? Discovery/preclinical research Clinical development Manufacturing Commercialization
1 PM	Rare Diseases PanelWhat is the biggest barrier to access to Orphan drugs in low-income countries? Price, Access and Availability Disease recognition and diagnosis Lack of patient education regarding new therapies Ultra-rarity of certain diseases creates barriers for BioPharma companies to pursue therapeutic
1-50 PM	Fireside Chat: Roy VagelosQuestion 1: Will pharma’s reputation continue its positive trend or return to negative base line beyond the pandemic Yes No Question 2: COVID-19 has put the spotlight on BioPharma as an essential player in the return to normalcy. What primary action do you think the industry needs to take to maintain a positive reputation beyond the pandemic? Continue developing innovative drug pricing models Increase drug pricing transparency Increase data sharing and transparency Improving availability and access in low income countries
2-35 PM	Digital & Data Sciences PanelWhere has COVID-19 had the biggest impact on your adoption and use of digital health technologies? Remote clinical trials and patient monitoring Real-world data collection and analysis Virtual drug launches

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Archive for the ‘BioTechnology – Venture Creation’ Category

Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes

Other related articles were published in this Open Access Online Scientific Journal, including the following:

AI in Drug Discovery: Data Science and Core Biology @Merck &Co, Inc., @GNS Healthcare, @QuartzBio, @Benevolent AI and Nuritas

Can Blockchain Technology and Artificial Intelligence Cure What Ails Biomedical Research and Healthcare

HealthCare focused AI Startups from the 100 Companies Leading the Way in A.I. Globally

AI in Psychiatric Treatment – Using Machine Learning to Increase Treatment Efficacy in Mental Health

Vyasa Analytics Demos Deep Learning Software for Life Sciences at Bio-IT World 2018 – Vyasa’s booth (#632)

New Diabetes Treatment Using Smart Artificial Beta Cells

Podcast Episodes by THE EUROPEAN VC

EPISODE #5: WILLIAM MCQUILLAN, FOUNDING PARTNER OF A VENTURE FIRM FOR GLOBALLY AMBITIOUS B2B COMPANIES

EPISODE #4: SHOMIT GHOSE, GP OF A SILICON VALLEY FIRM WITH 7 FUNDS UNDER ITS BELT

EPISODE #3 MICHAEL HANSEN, CEO OF A LEADING BUSINESS ANGEL ASSOCIATION IN EUROPE

EPISODE #2 STEPHAN MORAIS, FOUNDER AND MANAGING PARTNER OF A LEADING EARLY-STAGE DEEP TECH VC FIRM

EPISODE #1 MARC LOHRMANN, MANAGING PARTNER OF A 120 M€ LIFE SCIENCE FUND

World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Davos Agenda

Joe Biden Announced Science Team Nominations for the New Administration

Biden Science Team Nominations

The video link is

Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

Partial roster of over 170 VCs and Angels Confirmed to Speak and Judge:

Venture Summit Virtual Connect West

Where Innovation Meets Capital

March 16th -18th 2021

Register Today & Save

(Use promo code “LPBIVIP”)

Register Today & Save Click here http://bit.ly/3840e3D

(Use promo code “LPBIVIP”)

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as Chief Executive Officer and Arie Belldegrun, PhD (ex-Kite Therapeutics) on R&D

A new approach to biology

Foundational Papers in Biomolecular Condensates

Press releases and Dewpoint in the news

Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer

New York Times interviews Rick Young and Amy Gladfelter on the role of condensate “droplets” in COVID-19

Dewpoint Therapeutics raises $77 million to go after ‘undruggable’ diseases

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

Dewpoint Therapeutics to put ‘pedal to the metal’ with $77M round

Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates

21 biotech startups that are set to take off, according to top VCs

Proteins — and labs — coming together to prevent Rett Syndrome

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

Discovery of how cancer drugs find their targets could lead to a new toolset for drug development

Other related article published in this Online Open Access Scientific Journal include:

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma &amp; Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma &amp; Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

2021 summit- June 22. Marriott Cambridge, Massachusetts, USA

#USAIC20

Speakers

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020,

8 AM EST to 3-30 PM EST – Virtual Edition

@@@@

In these unprecedented times due to COVID-19, USAIC is offering Free Registration for its annual summit.

AGENDA & SPEAKERS

Panel Discussions:

Speakers

2020 World Medical Innovation Forum – COVID-19, AI – Life Science and Digital Health Investments, MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Follow Blog via Email

Recent Posts

Archives

Categories

Meta

Venture Summit Virtual Connect West, March 16^th -18^th 2021 featuring a dedicated Lifesciences / Healthcare Track

March 16^th -18^th 2021

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

14^th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020,